Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc has revealed early data from its Phase 2 EVOKE-02 study evaluating Trodelvy, in combination with Merck & Co Inc's Keytruda, for the treatment of advanced or metastatic non-small cell lung cancer. The preliminary results, presented at the IASLC 2023 World Conference on Lung Cancer, showed promising response and disease control rates. Gilead entered into two clinical trial collaboration and supply agreements with Merck in January 2022 to evaluate the combination of Trodelvy and Keytruda.
September 11, 2023 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead's Trodelvy, in combination with Merck's Keytruda, shows promising results in Phase 2 EVOKE-02 study for lung cancer treatment.
The positive preliminary results from the EVOKE-02 study could potentially boost Gilead's stock in the short term as it indicates progress in their oncology pipeline. The collaboration with Merck also strengthens their position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's Keytruda, in combination with Gilead's Trodelvy, shows promising results in Phase 2 EVOKE-02 study for lung cancer treatment.
The positive preliminary results from the EVOKE-02 study could potentially boost Merck's stock in the short term as it indicates the effectiveness of Keytruda in combination with other drugs. The collaboration with Gilead also strengthens their position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100